🔎 Trials Near Me

Hem › Icke-småcellig lungcancer › Delaware

Kliniska studier för Icke-småcellig lungcancer i Delaware

21 studier för Icke-småcellig lungcancer söker deltagare vid platser i Delaware.

Städer i Delaware

Officiell studietext (engelska)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Beebe South Coastal Health Campus, Millville
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
  • och 1 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Medical Oncology Hematology Consultants, Newark
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT04585750

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  • Beebe South Coastal Health Campus, Millville
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
  • och 1 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT07388524

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Beebe South Coastal Health Campus, Millville
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
  • och 1 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Medical Oncology Hematology Consultants, PA, Newark
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07361497

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  • Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
RekryterarFas 3
Ålder 18 till 100 · Alla kön · Uppdaterad 25 sep. 2026 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • ChristianaCare Health System, Newark
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07154290

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  • Research Site, Newark
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06868277

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

  • Bayhealth Cancer Center- Kent, Dover
  • Bayhealth Cancer Center- Sussex, Milford
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07028489

An External Control Arm Study in Non-Small Cell Lung Cancer

  • Bayhealth Medical Center, Kent Campus, Dover
  • Bayhealth Medical Center- Sussex Campus, Milford
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07174388

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Bayhealth Hospital Kent Campus, Dover
  • Bayhealth Hospital Sussex Campus, Milford
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 3 juni 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • Bayhealth Hospital Kent Campus, Dover
  • Bayhealth Hospital Sussex Campus, Milford
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 6 maj 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Bayhealth Hospital Kent Campus, Dover
  • Bayhealth Hospital Sussex Campus, Milford
RekryterarFas 2
18 Minutes · Alla kön · Uppdaterad 5 maj 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Beebe South Coastal Health Campus, Millville
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
  • och 1 fler
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 5 maj 2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Beebe South Coastal Health Campus, Millville
  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
  • och 1 fler
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 17 mars 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Newark
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.